Equillium Expands Scientific and Clinical Advisory Team
May 06, 2019 08:30 ET
|
Equillium
LA JOLLA, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present at H.C. Wainwright Global Life Sciences Conference
March 28, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Dan...
Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
February 26, 2019 16:07 ET
|
Equillium
Clinical trial evaluating EQ001 for the treatment of refractory lupus nephritis to commence in 2H 2019 Ongoing EQ001 development programs in acute graft-versus-host disease and severe asthma remain...
L’analyse de survie à long terme de l’étude de phase III randomisée démontre un bénéfice clinique évident de l’inolimomab dans le traitement de la SR-aGvHD
January 23, 2019 09:00 ET
|
Elsalys Biotech
L’analyse de survie à long terme de l’étude de phase III randomisée démontre un bénéfice clinique évident de l’inolimomab dans le traitement de la SR-aGvHD Le suivi des patients de l’étude de phase...
Long-term survival analysis of the randomised Phase III study shows a clear clinical benefit of inolimomab in SR-aGvHD
January 23, 2019 09:00 ET
|
Elsalys Biotech
Long-term survival analysis of the randomised Phase III study shows a clear clinical benefit of inolimomab in SR-aGvHD Follow-up of INO-107 Phase III study patients up to 8.5 years is the first...
Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease
December 19, 2018 08:06 ET
|
Small Logo
LA JOLLA, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
ExCellThera receives FDA orphan drug designation for ECT-001 for the prevention of graft-versus-host disease
December 17, 2018 08:05 ET
|
ExCellThera
MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced...
Incysus Therapeutics Announces Presentations at 2018 ASH and HAPLO Annual Meetings
November 28, 2018 16:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Equillium Reports Third Quarter 2018 Financial Results and Recent Highlights
November 15, 2018 16:07 ET
|
Equillium, Inc.
Completes Successful Initial Public Offering Raising Gross Proceeds of Approximately $71.6 Million On-Track for Early 2019 Initiation of Phase 1b/2 Trial of EQ001 in Acute Graft-Versus-Host Disease ...
Equillium to Present at Investor Conferences in November 2018
November 01, 2018 16:07 ET
|
Equillium, Inc.
LA JOLLA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...